|
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) |
|
|
|
| |
Kiniksa Pharmaceuticals International Plc Outlook |
On February 25 2025 the Kiniksa Pharmaceuticals International Plc provided following guidance
nnKiniksa Pharmaceuticals International plc. Financial Estimates and Portfolio Updates as of February 25, 2025nn
Kiniksa Pharmaceuticals recently reported its financial results for the fourth quarter and the full year of 2024, providing insight into its performance and strategic direction. The company has outlined its financial expectations for the upcoming year, particularly regarding the anticipated net product revenue from ARCALYST.
For the fiscal year 2025, Kiniksa forecasts that ARCALYST (rilonacept) will generate net product revenues in the range of $560 million to $580 million. This projection signifies a robust growth trajectory following its reported Q4 2024 net product revenue of $122.5 million and an annual total of $417 million for the full year.
Additionally, Kiniksa’s management has indicated confidence in its operational efficiency, with a commitment that the current operating plan is anticipated to maintain a positive cash flow on an annual basis.
Moreover, the company is advancing its clinical pipeline, with plans to initiate a Phase 2/3 clinical trial for KPL-387, targeting recurrent pericarditis, in mid-2025. Preliminary Phase 2 trial results are expected to be available in the second half of 2026. However, the development of Abiprubart for treating Sjögren’s disease will be discontinued, indicating a strategic shift in focus.
Kiniksa will hold a conference call and webcast today at 8:30 AM ET to further discuss these developments and financial forecasts, allowing stakeholders and investors to gain further clarity on the company’s outlook and ongoing initiatives.,
|
On January 13 2025 the Kiniksa Pharmaceuticals International Plc provided following guidance
nnKiniksa Pharmaceuticals International plc. Announces Preliminary 2024 Revenue Figures and 2025 Projectionsnn
Kiniksa Pharmaceuticals has recently shared its financial outlook, revealing preliminary net product revenue figures for 2024, alongside guidance for 2025. According to the report, the company achieved an impressive preliminary net product revenue of $416.4 million for 2024, marking a substantial growth of approximately 79% compared to the previous year.
Looking ahead, Kiniksa forecasts that its net product revenue for 2025 will fall within the range of $560 million to $580 million. This anticipated revenue growth underscores the company's positive trajectory and commitment to expanding its market presence.
Moreover, Kiniksa is projecting to maintain a cash flow positive status on an annual basis, indicating a strong financial position and sustainable operational practices.
- nnPreliminary 2024 revenue for ARCALYST (rilonacept)nn: $416.4 million (unaudited), reflecting around 79% year-on-year growth.
- nnExpected 2025 revenue for ARCALYSTnn: $560 million to $580 million.
- nnAnnual cash flownn: Kiniksa anticipates remaining cash flow positive.
These figures illustrate Kiniksa Pharmaceuticals' robust growth strategy, highlighting its product's increasing market adoption and the company's overall financial health.,
|
On October 29 2024 the Kiniksa Pharmaceuticals International Plc provided following guidance
nnKiniksa Pharmaceuticals International Plc. Updates Financial Guidance Post Q3 2024 Results and Recent Developments in Portfolio Strategynn
Kiniksa Pharmaceuticals has reported its financial results for the third quarter of 2024, showcasing significant progress in its operational and financial performance amidst an expanding product portfolio. The company's anticipated net product revenue for ARCALYST has been revised upwards, with projections now ranging between $410 million and $420 million for the entirety of 2024. Furthermore, Kiniksa reaffirms its commitment to maintaining positive cash flow on an annual basis.
In the third quarter of 2024, ARCALYST (rilonacept) generated impressive net product revenue of $112.2 million, reflecting a remarkable growth of 73% compared to the same quarter last year. This robust performance underscores the increasing adoption and market penetration of ARCALYST, which continues to play a pivotal role in Kiniksa's portfolio.
In addition to these financial highlights, Kiniksa has launched the Life DisRPted disease awareness campaign, aimed at enhancing understanding of recurrent pericarditis. This initiative features notable partnerships with NHL Hall of Famer Henrik Lundqvist and GRAMMY Award-winning singer-songwriter Carly Pearce, further elevating the campaign's visibility and impact.
Looking ahead, Kiniksa remains optimistic about its financial trajectory and operational capacity, anticipating consistent cash flow positivity throughout the year. The company will hold a conference call and webcast to discuss these results and future outlook at 8:30 am ET today.,
|
On July 23 2024 the Kiniksa Pharmaceuticals International Plc provided following guidance
nnKiniksa Pharmaceuticals International Plc. Reports Second Quarter 2024 Financial Results and Strategic Progressnn
Kiniksa Pharmaceuticals has announced its financial results for the second quarter of 2024, highlighting significant developments in its operational portfolio and an optimistic outlook for its revenue generation.
The company has revised its financial guidance upwards, projecting net product revenue for its key product ARCALYST (rilonacept) for the year 2024 to be in the range of $405 million to $415 million. This adjustment demonstrates Kiniksa's robust growth trajectory, with the recent quarter showing a remarkable Q2 net product revenue of $103.4 million for ARCALYST, reflecting an impressive 90% increase compared to the same period last year.
In addition to the positive revenue forecast, Kiniksa Pharmaceuticals has confirmed that it is well-positioned to maintain positive cash flow on an annual basis, reinforcing its financial stability in an evolving market landscape.
The company is also advancing its clinical development program for Abiprubart, which is now fully funded. The Phase 2b clinical trial focusing on Sjögren's disease is currently in the process of enrolling patients, indicating Kiniksa's commitment to expanding its treatment portfolio and addressing unmet medical needs.
To further discuss these developments, Kiniksa Pharmaceuticals will host a conference call and webcast at 8:30 AM ET today, providing stakeholders with insights into the company's strategy and future prospects.
|
On April 23 2024 the Kiniksa Pharmaceuticals International Plc provided following guidance
Kiniksa Pharmaceuticals Ltd. reported strong financial results for the first quarter of 2024, with ARCALYST (rilonacept) generating $78.9 million in net product revenue, marking an impressive 85% increase from the previous year. The company also announced that they expected ARCALYST's net product revenue to reach between $370 to $390 million for the entirety of 2024.
Additionally, Kiniksa Pharmaceuticals revealed their plans to start a Phase 2b trial for Abiprubart in Sjögren's Disease in the second half of 2024, showcasing their commitment to expanding their product portfolio. They also reassured investors by stating that their current operating plan would allow them to maintain positive cash flow on an annual basis.
Investors and stakeholders were invited to join a conference call and webcast at 8:30 am ET to learn more about Kiniksa Pharmaceuticals' recent achievements and future goals. Overall, the company's performance in the first quarter of 2024 bodes well for their continued growth and success in the pharmaceutical industry.
|
|
|
|
